The other is an injection of antibodies — sold under the brand name Beyfortus, known by its scientific name nirsevimab — given to infants before their first RSV season, and a few high-risk ...
New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, October 9, 2024. Sanofi advances its ambition to protect all ...
Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious ...
Some results have been hidden because they may be inaccessible to you